Heart Disease News and Research

Latest Heart Disease News and Research

BCBSNC receives CEO Cancer Gold Standard certification

Blue Cross and Blue Shield of North Carolina has received CEO Cancer Gold Standard accreditation, recognizing the organization's commitment to reducing the risk of cancer for employees and their families by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment.

29 Jul 2010

EMA recommends orphan medicinal product designation for XOMA 052 in treatment of Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the Committee for Orphan Medical Products of the European Medicines Agency (EMA) has adopted a positive opinion and recommends the granting of orphan medicinal product designation for XOMA 052, an antibody to interleukin-1 beta, for the treatment of Behcet's disease. Positive opinions are submitted to the European Commission for decision and are generally adopted within 30 days of receipt.

29 Jul 2010

ZOLL Medical receives PMDA approval to distribute AED Plus, AED Pro in Japan

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it has been granted approval by the Japanese Pharmaceutical and Medical Devices Agency to import and distribute the AED Plus and AED Pro in Japan.

29 Jul 2010

New study shows vitamin D deficiency is associated with arterial stiffness

Vitamin D deficiency is associated with arterial stiffness, a risk factor for heart disease and stroke, in black teens according to a new study accepted for publication in The Endocrine Society's www.endo-society.org. Black teens taking vitamin D supplementation of 2,000 international units per day had a decrease in central arterial stiffness.

29 Jul 2010

ZOLL Medical revenues for third-quarter fiscal 2010 up 17% to $111.3 million

ZOLL Medical Corporation, a manufacturer of resuscitation devices and software solutions, today announced that revenues for the third quarter of fiscal 2010 increased 17% to $111.3 million, compared to revenues in the third quarter of last year of $95.1 million. The third quarter 2010 results included approximately $5.0 million of revenue from the Temperature Management business, compared to $1.9 million of revenue in the third quarter of last year.

29 Jul 2010

Cord Blood America announces highlights for 6-month period ended June 30, 2010

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced highlights for the six-month period ended June 30, 2010. The Company believes the period was the most significant and eventful in its history.

29 Jul 2010

Devax's AXXESS Biolimus A9 Eluting Coronary Bifurcation Stent System receives CE Mark approval

Devax, Inc. announced today the company received CE Mark for its AXXESS™ Biolimus A9® Eluting Coronary Bifurcation Stent System, allowing the company to initiate sales in the European Union and other countries that recognize the CE Mark.

29 Jul 2010

U.S. Court of Appeals rules against Eli Lily's claims in Gemzar patent lawsuit

Sun Pharma today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the judgment of the U.S. District Court for the Eastern District of Michigan against Eli Lily and Co. finding certain claims of U.S. Patent No. 5,464,826 ("'826 patent") invalid. The appeal arose out of a lawsuit that Eli Lilly filed against Sun Pharma in connection with Sun Pharma's submission of an Abbreviated New Drug Application (ANDA) for a generic version of Gemzar®.

29 Jul 2010

Researchers examine why some obese people become diabetic while others do not

Why some obese people go on to become diabetic while others do not. It is common to find obese people - even morbidly obese people - who are healthier than their condition would normally allow.

29 Jul 2010

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

Abraxis BioScience, Inc., a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.

29 Jul 2010

American Red Cross encourages public to be trained in full CPR and use of AEDs

"Articles published today in The New England Journal of Medicine (NEJM) cite a pair of studies on Compression-Only Cardiopulmonary Resuscitation (CPR), sometimes called continuous chest compressions, Hands-Only CPR, or cardio cerebral resuscitation (CCR).

29 Jul 2010

Rotigotine provides clinically relevant improvements in RLS symptoms: Study

UCB today announced the results of a 6-month, randomized, double-blind, placebo-controlled clinical study, published in the journal Movement Disorders, showing that Neupro® (rotigotine transdermal system, 2 and 3 mg/24 hours) provided sustained, clinically relevant improvements in symptoms of Restless Legs Syndrome (RLS). The study also showed high rates of complete remission seen with rotigotine 2 mg or 3 mg/24 hours.

29 Jul 2010

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

Angiotech Pharmaceuticals, Inc. and partner Athersys, Inc. announced positive results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction, more commonly referred to as a heart attack.

29 Jul 2010

The Children's Hospital constructs new LEED-certified patient tower

The Children's Hospital has begun the construction of a 10-story, 350,000-square-foot addition. The $230 million expansion of a new patient tower initially will have 124 beds, with two floors of shelled space for additional future beds, bringing the total number of patient beds at Children's to around 500 upon full completion. The expansion also is expected to bring approximately 500 new jobs to the hospital's workforce. Children's anticipates admitting patients in the LEED-certified tower beginning in late 2012.

29 Jul 2010

Merit Medical second-quarter revenues increase 16% to $74.9 million

Merit Medical Systems, Inc., a leading manufacturer and marketer of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology, radiology and gastroenterology, today announced record revenues of $74.9 million for the quarter ended June 30, 2010, an increase of 16% over revenues of $64.8 million for the quarter ended June 30, 2009. Revenues for the six-month period ended June 30, 2010 were a record $142.4 million, compared with $123.2 million for the corresponding period in 2009, a gain of 16%.

29 Jul 2010

Study reveals high rate of atrial fibrillation in patients with early stages of CKD

Millions of Americans in the early stages of chronic kidney disease (CKD) are at an increased risk of having atrial fibrillation (AF) - a major risk factor for stroke - according to new research by investigators at Wake Forest University Baptist Medical Center.

29 Jul 2010

Sanofi-aventis U.S joins Dispensary of Hope's Continued Access Program

The Dispensary of Hope is pleased to announce that sanofi-aventis U.S., the U.S. affiliate of sanofi-aventis, a leading global pharmaceutical company, has become the latest pharmaceutical company to participate in the Dispensary's Continued Access Program, which provides uninsured patients with access to medicines that they otherwise couldn't afford.

29 Jul 2010

FDA Advisory Committee recommends approval of AstraZeneca's ticagrelor for Acute Coronary Syndromes

AstraZeneca today announced that the US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee recommended the FDA approve AstraZeneca's investigational drug ticagrelor for the reduction of thrombotic events in patients with Acute Coronary Syndromes.

29 Jul 2010

Response Biomedical closes $8 million common share private placement

Response Biomedical Corporation announced today that it has closed its previously announced private placement of common shares for gross proceeds of approximately $8 million. The Company issued 13,333,333 common shares at a price of C$0.60 per share.

29 Jul 2010

Athersys reports positive results from MultiStem phase I clinical trial in heart attack patients

Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.

29 Jul 2010

Heart Disease News and Research

Latest Heart Disease News and Research

BCBSNC receives CEO Cancer Gold Standard certification

EMA recommends orphan medicinal product designation for XOMA 052 in treatment of Behcet's disease

ZOLL Medical receives PMDA approval to distribute AED Plus, AED Pro in Japan

New study shows vitamin D deficiency is associated with arterial stiffness

ZOLL Medical revenues for third-quarter fiscal 2010 up 17% to $111.3 million

Cord Blood America announces highlights for 6-month period ended June 30, 2010

Devax's AXXESS Biolimus A9 Eluting Coronary Bifurcation Stent System receives CE Mark approval

U.S. Court of Appeals rules against Eli Lily's claims in Gemzar patent lawsuit

Researchers examine why some obese people become diabetic while others do not

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

American Red Cross encourages public to be trained in full CPR and use of AEDs

Rotigotine provides clinically relevant improvements in RLS symptoms: Study

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

The Children's Hospital constructs new LEED-certified patient tower

Merit Medical second-quarter revenues increase 16% to $74.9 million

Study reveals high rate of atrial fibrillation in patients with early stages of CKD

Sanofi-aventis U.S joins Dispensary of Hope's Continued Access Program

FDA Advisory Committee recommends approval of AstraZeneca's ticagrelor for Acute Coronary Syndromes

Response Biomedical closes $8 million common share private placement

Athersys reports positive results from MultiStem phase I clinical trial in heart attack patients

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Heart Disease News and Research

Latest Heart Disease News and Research

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in